Zhejiang Shapuaisi Pharmaceutical (603168.SH): Olodaterol hydrochloride eye drops obtained drug registration certificate
Shapuaisi (603168.SH) announced that the company has received approval from the National Medical Products Administration for the issuance of hydrochloride...
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that the company has received the Drug Registration Certificate for Olopatadine Hydrochloride Eye Drops approved and issued by the National Medical Products Administration. The approved Olopatadine Hydrochloride Eye Drops are used to treat eye itching related to allergic conjunctivitis.
Related Articles
Subsidiary of Qingdao Huicheng Environmental Technology Group(300779.SZ) successfully completes trial production of a demonstration project for comprehensive utilization of 200,000 tons of mixed waste plastics annually.
Tracking the Hong Kong stock market concept | Dalian Commodity Exchange urgently issues "boosting insurance and expanding boards" policy The photovoltaic industry chain ushered in an industrial turning point (with concept stocks)
China Galaxy Securities: Accelerating Commercialization of AI, Optimistic about AI Computing Power Chain, Byte Ecology, and Vertical SAAS as the Three Main Themes.
Subsidiary of Qingdao Huicheng Environmental Technology Group(300779.SZ) successfully completes trial production of a demonstration project for comprehensive utilization of 200,000 tons of mixed waste plastics annually.
Tracking the Hong Kong stock market concept | Dalian Commodity Exchange urgently issues "boosting insurance and expanding boards" policy The photovoltaic industry chain ushered in an industrial turning point (with concept stocks)
China Galaxy Securities: Accelerating Commercialization of AI, Optimistic about AI Computing Power Chain, Byte Ecology, and Vertical SAAS as the Three Main Themes.
